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Introduction
Anogenital human papillomavirus (HPV) infection is the most frequent sexually transmitted infection (STI) globally. [1] Low Risk (LR) HPV types 6 and 11 are the predominant causes of anogenital warts (AGW), a source of psychosocial distress, [2] and physical discomfort (including bleeding and itching). [3] Approximately 25% of AGW spontaneously regress, [3] but recurrence is common, resulting in high medical costs from repeated treatment. [4] There is little literature on the epidemiology of LR-HPV infection and AGW in Sub-Saharan Africa. Regional variations in LR-HPV prevalence varies from 2% in Western Africa, 4% in Southern Africa and 8% in Eastern Africa. [5] Similary, the prevalence of AGW ranges from 4-11% in Western, 2-14% in Southern and 3-11% in Eastern African regions. [6] The natural history of HPV infection is altered by HIV infection, and HPV prevalence is higher where HIV is more common or among individuals with HIV infection. [7] People living with HIV who have AGW tend to experience florid and prolonged clinical manifestations of AGW because of their impaired immune response. [8] Low CD4+ counts (<200 cells/μL) are associated with an increased risk of AGW. [9, 10] The impact of antiretroviral therapy (ART) on the prevalence and incidence of AGW is unclear, with conflicting findings from different studies. Some report that ART reduces incidence, [10] while other studies have shown that it does not reduce incidence. [7, 11] Three vaccines against HPV have been licensed, [12] two of which (quadrivalent and nonavalent) have activity against HPV types 6 and 11 that cause 90% of AGW. [13, 14] These vaccines have been steadily introduced into national immunization programmes in both high and low and middle income countries (LMIC), although the pace of introduction has been slower in LMIC. [15] Data from countries which have included the quadrivalent vaccine (against HPV6/11/16/18 types) in their vaccination programme show significant declines in the number of cases of AGW among vaccinated women and some herd-immunity effect in unvaccinated heterosexual men. [16] Decisions about which vaccine to include in a vaccination programme are driven by cost-effectiveness considerations. Since a high-burden of AGW is associated with significant costs to the health system in LMIC and this is worsened by high HIV prevalence, data on the prevalence, incidence and correlates of LR-HPV and AGW is important for informing vaccine programme decision-making and resource allocation. [12] To address this question, we analysed data from a cohort of women living with HIV (WLHIV) who participated in the HPV in Africa Research Partnership (HARP) study of cervical cancer screening in Burkina Faso and South Africa.
Materials and methods

Study design, population and sample collection
We conducted a prospective cohort study among WLHIV aged 25-50 years and residing in Ouagadougou, Burkina Faso (BF) and Johannesburg, South Africa (SA) between December 2011 and October 2012. A full description of the study design and procedures has been published elsewhere. [17] Briefly, enrolled participants were followed-up every 6 months up to 18 months. Data on clinical, socio-demographic and behavioural characteristics were collected by interviewer-administered questionnaire at each visit. The presence of AGW was assessed at enrolment and months 6, 12 and endline by trained nurse midwives during standardised pelvic examination. Cervical samples were collected using a Digene cervical sampler (Qiagen, Courtaboeuf, France) for HPV-DNA testing and genotyping, a swab from the ecto/endocervix to detect cervical sexually transmitted infections (STIs) by molecular methods and a vaginal smear to diagnose bacterial vaginosis and Candida albicans by Gram stain at both enrolment and endline visits. Blood samples were collected at enrolment to confirm HIV-1 serostatus, perform Herpes Simplex Virus-2 (HSV-2) and syphilis serologies as well as obtain baseline HIV-1 plasma viral load (PVL) measurement and CD4+ T-lymphocytes counts. The monitoring of CD4+ counts was done at subsequent 6-monthly visits.
Laboratory methods
HIV-1 serostatus was diagnosed using two rapid tests according to national guidelines. [18, 19] Testing for CD4+ cells was performed using FACScount (Becton-Dickinson, NJ). Plasma HIV-1 RNA was assessed using real-time PCR (Abbott RT HIV-1) in BF and COBAS Taqman (Roche Diagnostics) in SA, with a lower limit of detection of 40 copies/ml in both countries. Laboratories subscribed to international external quality assessment schemes such as the UK-NEQAS for CD4+ counts [20] and QCMD for HIV-1 PVL testing. [21] HSV-2 serology was performed using the Kalon1 gG2 ELISA (Kalon Diagnostics, UK) and syphilis serology by a combination of a Treponema pallidum haemagglutination (TPHA) and rapid plasma reagin (RPR; BioMérieux, Lyon, France in BF and Immutrep carbon antigen RPR, Omega Diagnostics in SA). Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis were detected using nucleic acid amplification tests, the Sacace simplex assays (Sacace, Como, Italy) in BF and the APTIMA Combo (Gen-Probe, San Diego, CA) in SA. The Nugent's score was used for vaginal flora reading of Gram-stained vaginal smears, with diagnosis of bacterial vaginosis made for scores !7, and examined for presence of Candida.
HPV DNA testing and genotyping was performed at the virology laboratory of University of Montpellier (UM) using INNO-LiPA HPV Genotyping Extra Assay (Innogenetics, Courtaboeuf, France). The assay is based on the amplification of a 65-bp fragment in the L1 gene and detects 28 HPV types, including all the high-risk or probable high-risk types (16, 18, 26, 
Statistical analysis
Any LR-HPV type infection was defined as detection of !1 of the 9 genotypes described above. LR-HPV type-specific persistence was defined as being positive for the same type at enrolment and endline. Type-specific LR-HPV incidence was defined as the proportion of women who were negative for a specific LR type at enrolment and positive for that type at endline. Prevalent AGW were defined as the presence of clinically-defined condyloma acuminata at the enrolment visit. Incident AGW were defined as the first documented occurrence of condyloma acuminata in a woman previously documented not to have AGW. Time to incident AGW was calculated from date of enrolment visit to the date of first AGW detection.
Descriptive statistics were used to summarize the prevalence of any LR-HPV infection and AGW. For bivariate analysis, socio-demographic, sexual behaviour, presence of other laboratory detected STI (as part of the screening process at enrolment), clinical signs and HIVrelated risk factors were chosen for assessment a priori as known correlates for HPV and AGW acquisition. As LR-HPV prevalence was common, associations with exposure variables were estimated from prevalence ratios obtained from logistic regression using marginal standardization to estimate prevalence ratios, and the delta method to estimate 95% confidence intervals (CIs). Associations between LR-HPV persistence and exposure variables were estimated with generalized estimating equations to account for multiple LR-HPV infection and multiple infection states (persistence and clearance). [23] To explore associations of any LR-HPV and AGW with HIV-related factors, pre-specified analyses included stratification by site, ART use, duration on ART ( or >2 years), HIV-1 viral suppression (< or !1000 copies/ ml) and CD4+ cell counts at enrolment. Logistic regression (Model 1) was used to identify independent associations between any prevalent LR-HPV or AGW and HIV-related factors, after adjustment for potential confounders (non HIV-related factors) that were associated with the outcomes in bivariate analysis at p<0.10. [24] A second logistic regression model (Model 2) adjusted for CD4+ cell count at enrolment in addition to factors adjusted for in Model 1 was run to explore associations with ART duration and HIV-1 viral suppression. Cox regression was performed to analyse predictors of incident AGW, with and without adjustment for potential confounders using the same model-building approach as described above under logistic regression. Data were analysed using Stata version 14 (Stata Statistical Software, College Station. TX: Stata Corporation).
Ethics statement
Study protocols were approved by the Ministry of Health in Burkina Faso (no. 2012-12-089), the University of the Witwatersrand in South Africa (no. 110707), and the London School of Hygiene and Tropical Medicine (no. 7400). All participants provided written informed consent.
Results
Study population
Of the 1473 women screened, 1238 (615 in BF and 623 in SA) were enrolled. The median age of participants was 36 (interquartile range [IQR], 31-42) years in BF and 34 (IQR, 30-40) years in SA. At enrolment, two-thirds of the participants were on ART (BF: 68.6% in BF; 65.2% in SA) and this is because enrolment was stratified in the ratio of 2 ART users: 1 non-ART user. In BF, the median CD4+ count was 417 (IQR, 315-606) cells/μL among ART-naive participants and 446 (IQR, 309-600) cells/μL among those on ART. In SA, the median CD4+ count was 448 (IQR, 353-614) cells/μL among ART-naive and 420 (IQR, 279-567) cells/μL among those on ART. A more detailed description of study participants has been published elsewhere. [17] 
Prevalence and correlates of LR-HPV infection
Almost all participants (n = 1215; 98.1%) had valid HPV genotyping results [BF = 594 (96.6%); SA = 621 (99.7%)]. The prevalence of any LR-HPV was lower in BF (27.1%) than in SA (40.9%) (p<0.001), as were the prevalence of the following LR types: 11 (1.5% vs. 5.3%, p<0.001), 44 (7.7% vs. 11.6%, p = 0.02), 70 (4.0% vs. 8.9%, p = 0.001) and 74 (6.2% vs. 10.0%, p = 0.02). Type 6 prevalence was similar in both countries (BF 5.7% vs. SA 5.3%). Type 44 was the most prevalent LR-HPV type, for both countries ( Fig 1A) . In both countries, LR-HPV prevalence was lower among women who have had pregnancies compared to those who have been never pregnant (BF: adjusted Prevalence Ratio (aPR) = 0.54; 95%CI: 0.29-0.99 vs. SA: aPR = 0.62; 95%CI: 0.44-0.89). In BF alcohol use (aPR = 1.41; 95%CI: 1.01-1.97) and self-reported consistent condom use (aPR = 1.93; 95%CI: 1.07-3.47) were associated with higher LR-HPV prevalence. In SA LR-HPV prevalence was higher among women without a regular sexual partner compared to those with a regular partner (aPR = 2.39; 95%CI: 1.37-4.19) ( Table 1) .
Associations between prevalent LR-HPV infection and HIV-related factors
Of the 1215 women with valid HPV results, 32 (2.6%) reported that they were not on ART at enrolment despite undetectable HIV-1 PVL (BF = 24; SA = 8). Given the uncertainty of their ART status, these women were excluded from HIV-related factors analyses. Further analyses were conducted on the remaining 1183 participants (BF = 570; SA = 613) to determine the effect of HIV-related factors on any LR-HPV prevalence (Table 2) . In both countries, LR-HPV prevalence was higher among women with a low CD4+ count (<200 cells/μL vs. >500 cells/ μL; Model 1 BF: adjusted Odds Ratio (aOR) = 1.37; 95%CI: 1.13-1.65 vs. Model 1 SA: aOR = 1.15; 95%CI: 0.99-1.33) ( Table 2) . Among ART users, a low CD4+ count was also associated with a higher risk of prevalent LR-HPV infection (Model 1 BF: aOR = 1.41; 95%CI: 0.89-2.24 vs. Model 1 SA: aOR = 1.58; 95%CI: 1.06-2.34). The duration on ART (i.e. >2 years vs. 2 years on ART) and HIV-1 PVL at enrolment were not significantly associated with prevalent LR-HPV infection (Table 2 ).
Incidence and persistence of LR-HPV infection and effect of HIV-related factors
Overall, 963/1238 (77.8%) WLHIV attended the endline visit at a median 16 (IQR, 15.6-16.8) months and the majority (922) had HPV-genotyping results at both enrolment and endline (BF = 476; SA = 446). Of these, 264 (28.7%) had incident LR-HPV of any type during followup. The incidence of any LR-HPV infection was lower in BF compared to SA (BF: 25.8% vs. SA: 31.6%, p = 0.05). This was also true for most individual types (11, 54 and 74) with the exception of types 44 (BF: 4.7% vs. SA: 0.9%, p = 0.01) and 69/71 (BF: 8.5% vs. SA: 4.5%, p = 0.02) which were significantly higher in BF compared to SA (Fig 1B) .
A third of WLHIV (310/922) were defined as having persistent LR-HPV infection; the total number of persistent infections was 396 (BF = 156; SA = 240). The frequency of persistent infection of any LR-HPV at endline was similar in both countries (BF: 33.3% vs. SA: 30.4%; p = 0.54). Persistence for individual types was largely similar between the two countries ( Fig  1C) . A low CD4+ count (i.e. <200 cells/μL vs. >500 cells/μL) was associated with a higher likelihood of having persistent LR-HPV infection. The association was stronger among ART users (Model 1 BF: aOR = 3.21; 95%CI: 0.90-11.40 vs. Model 1 SA: aOR = 3.33; 95%CI: 0.96-11.55). The duration on ART at enrolment and HIV-1 PVL were not significantly associated with persistent LR HPV infection (S1 Table) .
Prevalent AGW and effect of prevalent LR-HPV infection and HIV-related factors
Overall, 81 (6.7%) WLHIV had AGW detected at enrolment; the prevalence did not vary by country (BF: 7.5% vs. SA: 5.7%; p = 0.21). In univariate analysis (data not shown), prevalent AGW were associated with age, number of partners in the last 3 months before enrolment, presence of genital ulcers for both countries and being HSV-2 seropositive in BF or having bacterial vaginosis in SA. Infection with any LR-HPV type, multiple LR-HPV infections, and infection with types 6 (Model 2 BF aOR = 3.14; 95%CI: 1.11-9.01 and SA aOR = 1.79; 95%CI: 0.49-6.51) and 11 (Model 2 BF aOR = 20.12; 95%CI: 4.06-99.71 and SA aOR = 7.90; 95%CI: 3.11-20.09) were significantly associated with prevalent AGW (Table 3 (Table 3) .
AGW incidence and association with LR HPV infection and HIV-related factors
A total of 32 new AGW events (BF = 16; SA = 16) were recorded for the 992 (BF = 468; SA = 524) WLHIV who were followed up for a total of 1390 person-years. The overall AGW 
Discussion
We found that the prevalence and incidence of LR-HPV infection in this population were high and consistent with other studies of WLHIV in sub-Saharan Africa. [7, 25, 26] We also found that infections with types 6 and 11 were strongly associated with both prevalent and incident (type 6 only) AGW, which confirms the literature. [7, 27] The prevalence of AGW in both countries is similar to what has been reported among HIV-1 seropositive female sex workers in Burkina Faso, [7] but the AGW incidence (BF = 2.47 and SA = 2.33 per 100 person-years) was almost 3-fold lower than the 7.14 per 100 person-years reported by Low et al., [7] possibly owing to the repeated occupational exposure and lower proportion of WLHIV on ART (10%) in that population. We found that low enrolment CD4+ cell count was associated with a higher prevalence and persistence of LR-HPV as well as a higher prevalence and incidence of AGW. This is consistent with previous studies reporting CD4+ count as a strong predictor of HPV infection and AGW development. [9, 10] A longer duration (>2 years) of ART was not protective per se against prevalent LR-HPV infection, incident LR-HPV infection and incident AGW, confirming other studies findings. [7, 11] This suggests that other co-factors such as adherence to ART, HIV-1 PVL suppression and immunological reconstitution (as measured by increases in CD4+ count) are also important for the control of HPV infection and progression to associated disease. We also found that, as reported in previous studies, non-HIV related factors such as alcohol use, number of recent sexual partners, changes in vaginal flora and coinfection with other STIs were significant co-factors for LR-HPV infection and AGW. [6, 7] In contrast to reports from previous studies, we did not find significant association between smoking or hormonal contraception with LR-HPV infection or AGW. [6, 28, 29] It was also surprising to note that LR-HPV prevalence was high among women who reported consistent condom use. The reason why infection prevalence was high among women who reported consistent condom use is not known. However, this could be related to social desirability bias which meant that women with high risk sexual behaviours reported high condom use.
Limitations of the study include the absence of HIV-1 PVL monitoring, in particular at endline and the possible subjective nature of clinical examination for AGW detection without histological confirmation leading to possible misclassification. Cervical LR-HPV infection rather than vaginal/vulval LR-HPV infection was measured which would have been more appropriate given the frequent external location of AGW. This can lead to difficulties in ascribing causality. However, cervical HPV infection has been used previously in determining associations with AGW. [7] Despite these limitations, this study had a number of strengths, including its longitudinal design, availability of AGW data at four time points and availability of genotyping data at both enrolment and endline visits. More importantly, the study contributes data on the epidemiology of LR-HPV infection and AGW from two sub-Saharan African countries with different HIV epidemics and this allows the findings to be extended to a range of countries and settings in the region.
Conclusions
This study shows that WLHIV in sub-Saharan Africa are at high risk of LR-HPV infections and AGW. AGW were associated with HPV 6/11 and these findings support the argument for the use of quadri-or nano-valent HPV vaccines for the prevention of AGW among WLHIV. Effective use of ART with immunological reconstitution could also help control the burden of AGW among WLHIV in the region. (Table 3) , 5 were excluded from analysis as they were ART-naïve but with undetectable viral load and similarly of the 240 infections at enrolment in South Africa (Table 3) 
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